antimicrobi
resist
amr
pose
huge
threat
public
health
worldwid
carbapenemresist
enterobacteriacea
cre
categor
one
urgent
threat
center
diseas
control
prevent
cdc
kill
almost
half
inpati
get
bloodstream
infect
one
resist
determin
mbl
includ
imipenemas
imp
verona
integronencod
vim
recent
new
delhi
ndm
zn
ii
contain
enzym
activ
nucleophil
water
cleav
ring
confer
onto
bacteria
resist
last
resort
carbapenem
bicycl
current
particular
bacteria
caus
variou
type
infect
spread
global
sinc
first
detect
geograph
dissemin
resist
rais
great
constern
resist
highli
transfer
among
mani
preval
human
pathogen
includ
enterobacteriacea
pseudomona
spp
acinetobact
usual
accompani
gene
encod
resist
even
organ
arm
multipl
resist
almost
class
antibiot
avail
current
therapeut
option
avail
treat
infect
socal
superbug
combin
therapi
compris
avail
antibiot
nonantibiot
usual
inhibitor
consid
econom
effect
altern
develop
monotherapi
new
combin
therapi
current
use
clinic
treat
infect
sbl
posit
bacteria
eg
amoxicillinclavulan
piperacillintazobactam
recent
ceftazidimeavibactam
howev
till
equival
therapi
avail
mblsposit
bacteri
infect
mbl
inhibitor
clinic
approv
clinic
use
sbl
inhibitor
effect
toward
remain
signific
challeng
design
mbl
inhibitor
particularli
broadspectrum
mbl
inhibitor
given
structur
divers
mechanist
complex
though
chelat
agent
ethylenediaminen
n
edta
aspergillomarasmin
significantli
inhibit
mbl
indiscrimin
chelat
zn
ii
might
result
untoward
effect
natur
endogen
metalloprotein
critic
mani
biolog
current
organ
moleculebas
mbl
inhibitor
includ
pyridin
dicarboxyl
thiolderiv
natur
product
even
carbapenem
analog
design
mimick
substrat
specif
type
mbl
shown
reduc
mbl
activ
specif
type
vitro
anim
howev
still
remain
question
whether
inhibitor
approv
clinic
usag
moreov
inhibitor
may
readili
encount
microbi
resist
owe
rapid
evolut
therefor
effect
therapeut
strategi
urgent
need
metal
compound
use
antimicrobi
agent
auranofin
gold
antirheumat
agent
exert
broadspectrum
bactericid
activ
via
inhibit
bacteri
thioredoxin
silver
nitrat
gallium
nitrat
enhanc
antibiot
activ
multidrug
resist
bacteria
antibiot
bismuth
bi
iii
compound
colloid
bismuth
subcitr
cb
ranitidin
bismuth
citrat
rbc
clinic
use
drug
combin
antibiot
treat
helicobact
pylori
h
pylori
associ
infect
even
clarithromycin
metronidazoleresist
strain
confer
resist
even
usag
long
period
thu
reus
metal
compound
consid
promis
altern
deal
current
crisi
consid
mbl
zinc
zn
ii
contain
enzym
use
metal
compound
inactiv
activ
may
repres
new
approach
discoveri
mbl
inhibitor
screen
panel
metal
compound
show
antiulc
drug
cb
relat
bi
iii
compound
exhibit
potent
activ
toward
inhibit
cellbas
enzymebas
assay
combin
use
cb
antibiot
restor
antibiot
activ
also
significantli
reduc
evolut
escherichia
coli
e
coli
moreov
cb
boost
vivo
efficaci
murin
periton
model
crystallograph
biophys
studi
demonstr
bi
iii
compound
irrevers
inactiv
uniqu
mechan
one
bi
iii
replac
two
zinc
ion
activ
site
cystein
activ
site
shown
play
pivot
role
activ
bi
iii
compound
studi
strongli
suggest
bi
iii
drug
compound
might
reposit
develop
first
broadspectrum
inhibitor
mbl
particular
class
mbl
studi
provid
new
opportun
design
effect
broadspectrum
mbl
inhibitor
treatment
infect
caus
mblposit
bacteria
togeth
antibiot
antimicrobi
activ
metal
compound
antibiot
initi
screen
clinic
isol
e
coli
hereaft
denot
ndmhk
supplementari
tabl
strain
confirm
resist
carbapenem
meropenem
mer
judg
minim
inhibitori
concentr
mic
higher
breakpoint
valu
mer
enterobacteriacea
defin
european
committe
antimicrobi
suscept
test
eucast
growth
inhibit
examin
presenc
panel
metal
compound
mer
subinhibitori
concentr
h
bacteri
inocul
primari
screen
gave
rise
two
activ
metal
compound
ie
bismuth
nitrat
bi
nit
gallium
nitrat
growth
inhibit
base
optic
densiti
od
read
supplementari
fig
bi
nit
show
higher
bioactiv
gallium
nitrat
subsequ
colonyform
unit
cfu
count
surprisingli
coloni
observ
agar
plate
serial
dilut
bi
nit
use
supplementari
fig
impli
bi
iii
compound
may
facilit
mer
kill
produc
given
clinic
usag
treatment
h
pylori
infect
cb
select
evalu
whether
repurpos
treat
mblposit
bacteri
infect
togeth
antibiot
first
examin
whether
cb
fig
resensit
produc
toward
carbapenem
use
mer
exampl
standard
checkerboard
microdilut
method
use
monitor
interact
mer
cb
ndmhk
strain
cure
pndmhk
serv
control
denot
ndmhk
pcv
plasmid
cure
variant
mic
mer
cb
show
minor
growth
inhibit
toward
either
fig
neg
bacteria
fig
even
howev
mer
cb
use
combin
mic
valu
mer
ndmhk
gradual
drop
fig
tabl
empir
suscept
level
accord
fraction
inhibitori
concentr
index
fici
determin
supplementari
tabl
indic
synergist
interact
fici
defin
synerg
contrast
synerg
detect
ndmhk
pcv
fici
shown
fig
potent
synergi
also
demonstr
time
kill
curv
show
popul
ndmhk
exponenti
phase
significantli
lower
upon
exposur
drug
combin
mer
cb
h
fig
cb
could
reduc
mic
valu
mer
toward
neg
strain
suggest
cb
might
abolish
enzymat
activ
examin
whether
cb
abl
inhibit
enzymat
activ
carri
steadyst
kinet
use
mer
substrat
observ
dosedepend
inhibit
activ
relat
mbl
eg
cb
fig
ultim
lead
activ
mbl
inhibit
approxim
compar
halfmaximum
inhibitori
concentr
valu
cb
observ
determin
respect
fig
tabl
consist
cellbas
studi
result
enzymat
assay
confirm
capabl
cb
restor
mer
antimicrobi
activ
attribut
inhibit
activ
also
observ
similar
synerg
pattern
combin
cb
mer
checkerboard
assay
panel
enterobacteri
strain
ie
e
coli
klebsiella
pneumonia
ndmk
pneumonia
citrobact
freundii
ndmc
freundii
harbor
differ
mbl
fig
supplementari
tabl
collect
show
cb
potenti
broadspectrum
inhibitor
mbl
regardless
sub
type
enterobacteriacea
produc
search
bi
iii
compound
exhibit
higher
activ
toward
inhibit
mbl
synthes
seri
relat
bi
iii
compound
supplementari
fig
examin
inhibitori
activ
cellbas
synergi
assay
result
demonstr
test
bi
iii
compound
synerg
mer
adjudg
fici
valu
rang
mic
mer
decreas
supplementari
fig
supplementari
tabl
four
typic
bi
iii
compound
shown
tabl
exemplifi
potent
synergi
mer
differ
mbl
produc
particular
complex
bismuth
nacetylcystein
bi
nac
exhibit
potent
inhibitori
activ
differ
mblposit
strain
decreas
mic
mer
e
coli
respect
fici
valu
rang
supplementari
fig
combin
mer
bi
nac
abl
erad
bacterium
complet
within
h
supplementari
fig
excel
inhibitori
activ
may
aris
cooper
inhibit
bi
iii
ion
nac
ligand
dissoci
bi
nac
well
elev
cellular
uptak
bi
iii
supplementari
fig
moreov
bactericid
activ
mer
mblposit
bacteri
strain
also
boost
bi
iii
compound
manifest
decreas
minim
bactericid
concentr
mbc
mer
tabl
supplementari
tabl
enzymebas
assay
demonstr
bi
iii
compound
abl
inhibit
mbl
compar
valu
tabl
among
bi
nit
exhibit
potent
inhibitori
effect
cb
outperform
compound
inhibit
result
show
inhibitori
effect
mbl
gener
observ
bi
iii
compound
suffici
demonstr
inactiv
mbl
attribut
primarili
bi
iii
ion
investig
bi
iii
compound
exert
inhibitori
activ
shown
fig
addit
bi
iii
bi
nta
led
appear
absorpt
band
nm
characterist
ligandtomet
charg
transfer
lmct
band
intens
increas
level
molar
ratio
bi
protein
suggest
bound
one
bi
iii
cystein
residu
involv
bind
fit
titrat
curv
nonlinear
kd
calcul
take
account
bind
bi
iii
nta
log
ka
appar
dissoci
constant
kd
calcul
one
cystein
activ
site
sitedirect
mutat
alanin
abolish
enzymat
activ
ident
condit
confirm
import
residu
enzymat
accordingli
cb
concentr
exhibit
much
reduc
inhibitori
effect
fig
phenomenon
also
note
suscept
test
mic
mer
produc
remain
unchang
even
presenc
cb
supplementari
tabl
consist
bind
capac
bi
iii
reduc
significantli
ca
molar
equival
bi
iii
bound
mutant
reveal
induct
coupl
plasma
mass
spectrometri
icpm
result
demonstr
activ
site
play
pivot
role
bi
iii
inhibit
activ
use
cellular
thermal
shift
assay
method
examin
chang
thermal
stabil
target
protein
upon
drug
found
supplement
bi
iii
compound
bacteri
cell
led
similar
shift
proteinmelt
temperatur
ca
fig
supplementari
fig
melt
temperatur
remain
almost
unchang
upon
treatment
bismuth
compound
mutant
strain
supplementari
fig
indic
import
bind
bi
iii
cell
next
examin
whether
bind
bi
iii
induc
zn
ii
releas
icpm
shown
fig
addit
increas
concentr
cb
nativ
znbound
result
gradual
decreas
stoichiometri
zn
ii
accompani
increas
bind
stoichiometri
bi
iii
eventu
ca
molar
equival
zn
ii
displac
wherea
molar
equival
bi
iii
bound
enzym
phenomenon
unpreced
case
one
bi
iii
ion
displac
one
zn
ii
ion
enzym
significantli
inhibit
activ
bi
iii
essenti
irrevers
supplement
molar
equival
zn
ii
led
activ
restor
bibound
owe
less
extent
bi
iii
replac
zn
ii
enzym
supplementari
fig
contrast
full
recoveri
fig
limit
proteolysi
purifi
solubl
apobound
znbound
bibound
also
perform
explor
impact
bi
iii
protein
stabil
found
bibound
well
apobound
readili
degrad
supplementari
fig
contrast
znbound
resist
proteolysi
proteinas
subsequ
examin
chang
enzym
kinet
vari
bi
iii
concentr
addit
bi
iii
result
decreas
appar
vmax
bi
iii
concentr
increas
relev
lineweav
burk
plot
indic
either
typic
noncompetit
irrevers
inhibit
fig
molecular
mechan
inhibit
mbl
bi
iii
compound
investig
xray
crystallographi
attempt
direct
cocrystal
bibound
form
success
due
amorph
precipit
readili
form
virtual
crystal
condit
examin
thu
crystal
soak
cb
use
first
crystal
determin
highresolut
nativ
structur
supplementari
fig
highest
resolut
obtain
far
facilit
diffus
bi
iii
ion
crystal
lattic
zn
ii
ion
nativ
crystal
remov
immers
crystal
pool
cryosolut
contain
metalchel
agent
ethylenediaminetetraacet
edta
bind
bi
iii
protein
confirm
xray
excit
spectrum
show
excit
peak
bismuth
around
kev
zinc
peak
around
kev
supplementari
fig
two
data
set
collect
bibound
crystal
one
peak
posit
remot
posit
bismuth
absorpt
edg
data
set
show
clear
anomal
peak
activ
site
anomal
peak
data
set
collect
signific
indic
presenc
bi
iii
crystal
lattic
shown
fig
signific
overal
conform
chang
observ
bibound
znbound
rmsd
ca
subtl
conform
chang
observ
activ
site
fig
structur
refin
use
anomal
signal
show
bi
iii
exhibit
two
altern
conform
activ
site
bi
iii
locat
two
zn
ii
ion
slightli
closer
site
nativ
structur
major
conform
occup
apart
residu
coordin
well
origin
bind
also
involv
bi
iii
coordin
togeth
water
molecul
form
trigon
prismat
geometri
fig
bi
iii
locat
slightli
near
site
nativ
structur
minor
conform
much
less
tendenc
occup
supplementari
fig
bi
iii
coordin
water
molecul
form
distort
tetrahedr
geometri
supplementari
tabl
bond
length
bi
iii
side
chain
amino
acid
overal
longer
zn
ii
gener
fig
supplementari
tabl
consist
larger
ionic
radiu
bi
iii
zn
ii
crystallograph
data
agreement
biophys
character
one
bi
iii
ion
replac
two
zn
ii
crucial
bi
iii
bind
spite
clinic
applic
treatment
h
pyloriassoci
diseas
bismuth
drug
cb
rbc
confer
resist
even
use
long
period
time
importantli
combin
bismuth
drug
antibiot
significantli
increas
erad
rate
drugresist
h
contribut
capabl
target
multipl
biolog
typic
featur
metalloag
uniqu
properti
might
endow
potenc
bi
iii
compound
cope
resist
issu
assess
whether
bi
iii
compound
exhibit
resistanceproof
characterist
mblposit
bacteria
ie
ndmhk
mutant
prevent
concentr
mpc
determin
mer
absenc
presenc
differ
concentr
cb
found
mer
alon
unabl
kill
highlevel
resist
mutant
even
mic
mpc
fold
mic
contrast
increas
cb
concentr
number
mutant
coloni
declin
significantli
shown
heat
map
fig
observ
mutat
frequenc
rang
supplementari
tabl
howev
reduct
mutant
coloni
note
strain
ndmhk
pcv
fig
mer
mpc
lower
mic
ndmhk
cb
bi
nac
use
fig
left
bar
supplementari
fig
contrast
less
mutat
prevent
observ
cb
ndmhk
pcv
fig
right
bar
although
hyperproduct
note
shown
inset
fig
combin
therapi
significantli
suppress
evolut
highlevel
resist
period
passag
ndmhk
fig
phenomenon
observ
ndmhk
pcv
impli
mutat
prevent
bacteria
bi
iii
compound
attribut
inhibit
enzym
inde
mic
presenc
cb
vs
absenc
cb
found
mer
e
coli
rosetta
cell
ndmrosetta
ox
supplementari
tabl
confirm
abil
cb
restor
antibiot
activ
bacteria
hyperproduct
consid
low
toxic
cb
human
accept
mutat
frequenc
combin
antibiot
cb
potenti
therapeut
applic
first
investig
feasibl
cb
restor
antimicrobi
activ
antibiot
treat
bacteri
infect
mammalian
cell
cultur
infect
model
canin
kidney
mdck
epitheli
cell
infect
ndmhk
multipl
infect
moi
h
infect
mdck
cell
expos
cb
mer
monotherapi
combin
therapi
overnight
lyse
subsequ
enumer
bacteria
attach
penetr
transcytos
therein
agar
plate
result
show
viabl
bacteri
load
still
level
cfu
even
mer
mic
use
howev
drop
greatli
level
cfu
mer
cb
use
combin
fig
addit
decreas
bacteri
load
also
observ
bacteriainvad
model
supplementari
fig
evalu
vivo
efficaci
drug
combin
rescu
mice
bacteriuminduc
mortal
use
periton
model
femal
balbc
mice
infect
system
lethal
dose
ndmhk
presenc
mucin
mucin
macromolecular
compon
mammalian
mucu
commixtur
mucin
use
enhanc
bacteri
pathogen
mous
periton
wherea
mice
show
morbid
mortal
mucin
use
alon
infect
mice
administr
vehicl
control
mer
cb
monotherapi
combin
therapi
h
post
infect
follow
twicedaili
treatment
via
ip
inject
fig
monotherapi
cb
fail
protect
mice
death
within
h
half
mice
mer
group
also
die
next
day
post
infect
endpoint
experi
mer
rescu
two
eight
mice
howev
preexperi
mer
ident
dose
cure
mice
infect
lethal
dose
ndmhk
pcv
supplementari
fig
contrast
combin
therapi
effect
postpon
death
mice
led
increas
mice
surviv
rate
addit
bacteri
clot
observ
direct
visual
inspect
infect
site
dissect
mice
receiv
combin
therapi
supplementari
fig
similar
result
obtain
murin
periton
model
without
mucin
mice
surviv
h
mer
cb
coadministr
supplementari
fig
taken
togeth
demonstr
vitro
antimicrobi
activ
combin
mer
cb
could
effect
convert
vivo
efficaci
carbapenem
antibiot
class
choic
treatment
seriou
infect
caus
enterobacteriacea
produc
ampc
type
enzym
extendedspectrum
clinic
util
howev
greatli
challeng
emerg
carbapenemas
ie
sbl
difficulttotreat
mbl
extrem
broad
substrat
spectrum
almost
except
well
resist
commerci
avail
inhibitor
sbl
particular
one
widespread
threaten
mbl
bind
hydrolyz
almost
antibiot
zn
ii
cofactor
therefor
effect
therapi
avail
current
class
antibiot
colistin
fosfomycin
though
exhibit
antimicrobi
activ
mblposit
bacteria
usual
suffer
sever
side
effect
limit
drug
restrain
medic
therapi
mbl
produc
thu
altern
strategi
need
develop
effect
mbl
inhibitor
herein
demonstr
potenti
reposit
antih
pylori
drug
cb
fig
new
class
mbl
inhibitor
bismuth
drug
cb
combin
antibiot
recommend
firstlin
treatment
h
pylori
infect
even
overcom
clarithromycin
metronidazol
differ
heavi
metal
ion
bismuth
drug
exhibit
neglig
toxic
human
attribut
glutathion
multidrugresist
proteinmedi
dispos
human
current
accept
therapeut
daili
dose
cb
europ
deliv
approxim
mg
equival
bismuth
oxid
intox
document
cb
recommend
dosag
treatment
peptic
ulcer
diseas
seriou
advers
effect
associ
combin
data
show
batteri
bi
iii
compound
includ
cb
inhibit
micromolar
level
excitingli
exhibit
synergi
upon
cotreat
mer
resist
strain
reflect
fici
valu
signific
decreas
mic
tabl
activ
mer
restor
level
similar
sensit
strain
higher
activ
bi
nac
toward
mblsposit
bacteria
may
provid
rational
develop
potent
bi
iii
compound
complex
bi
iii
ligand
could
increas
bi
iii
uptak
well
possess
high
affin
toward
chelat
zn
ii
time
biophys
character
reveal
uniqu
featur
one
bi
iii
bind
activ
site
accompani
releas
two
zn
ii
cofactor
fig
c
lead
abolish
mbl
activ
vitro
vivo
unexpect
phenomenon
might
attribut
distinct
properti
bi
iii
ie
rel
larg
size
high
coordin
number
moreov
activ
site
locat
shallow
groov
encompass
sever
loop
zn
ii
coordin
confer
conform
flexibl
residu
effici
substrat
bind
catalysi
turnov
consist
thiolphil
natur
cystein
critic
bind
bi
iii
reveal
mutagenesi
studi
eg
well
crystal
structur
show
involv
bind
bi
iii
conform
organ
mbl
inhibitor
inactiv
enzym
bind
substrat
site
specif
type
inhibitor
unlik
develop
broadspectrum
inhibitor
mbl
given
structur
divers
enzym
activ
site
contrast
bi
iii
compound
inactiv
enzym
replac
zn
ii
bi
iii
ion
via
critic
residu
cystein
activ
site
base
uniqu
mechan
employ
bi
iii
inactiv
strongli
suggest
bi
iii
compound
serv
broadspectrum
inhibitor
class
mbl
although
select
showcas
studi
tabl
monozinc
ii
class
mbl
cystein
found
activ
site
howev
remain
seen
whether
access
bi
iii
fast
bi
iii
zn
ii
exchang
could
given
structur
rigid
natur
class
mbl
activ
may
warrant
investig
see
whether
bi
iii
compound
also
inhibit
class
mbl
contrast
organ
moleculebas
inhibitor
may
easili
encount
resist
owe
rapid
evolut
variant
mbl
occur
case
inhibitorresist
ir
combin
cb
mer
significantli
suppress
develop
highlevel
resist
produc
may
due
reduc
use
mer
combin
andor
reduc
protein
level
bacteri
cell
treat
cb
supplementari
fig
nevertheless
mic
mer
still
rais
end
passag
compar
origin
strain
control
owe
hyperproduct
confirm
western
blot
fig
whether
due
mutat
promot
region
gene
andor
high
copi
number
plasmid
carri
bla
gene
may
warrant
studi
futur
addit
use
oral
drug
tripl
quadrupl
therapi
h
pyloriassoci
infect
intraven
intramuscular
use
bi
iii
compound
document
almost
centuri
enlist
bismuth
drug
combat
carbapenemresist
system
infect
vivo
notabl
periton
coadministr
cb
compar
dose
current
fdaapprov
human
dose
mgkg
boost
effect
mer
lead
increas
mous
surviv
time
reduc
mortal
mous
infect
highli
lethal
ndmhk
fig
howev
mice
surviv
eventu
possibl
due
limit
studi
pharmacokinet
pharmacodynam
bismuth
drug
circumst
nevertheless
robust
vitro
preliminari
vivo
result
provid
solid
foundat
develop
bi
iii
metallodrug
antibiot
adjuv
treat
infect
caus
mblproduc
bacteria
wider
clinic
context
exampl
bi
iii
known
preferenti
accumul
local
high
concentr
bi
iii
may
render
better
therapeut
effect
mous
kidney
urinari
tract
infect
model
moreov
approv
drug
cb
render
rapid
econom
rout
clinic
trial
even
patent
success
summari
demonstr
cb
relat
bismuth
compound
class
novel
potent
inhibitor
mbl
vitro
vivo
distinct
previous
report
organ
moleculebas
inhibitor
bi
iii
irrevers
inhibit
mbl
via
uniqu
metal
displac
mechan
cystein
residu
activ
site
critic
bismuth
coordin
thu
anticip
cb
bismuth
compound
reposit
develop
new
class
broadspectrum
inhibitor
mbl
given
bi
iii
compound
alreadi
clinic
use
drug
select
toxic
toward
pathogen
broadspectrum
mbl
inhibitor
togeth
antibiot
cotherapi
undoubtedli
open
new
horizon
treatment
infect
caus
mblposit
bacteria
inde
combin
use
resist
breaker
exist
antibiot
repres
new
econom
therapi
effect
solv
problem
antibiot
meropenem
purchas
tci
chemic
shanghai
kanamycin
sulfat
luriabertani
lb
broth
powder
lb
agar
purchas
affymetrix
chemic
purchas
sigmaaldrich
unless
otherwis
state
bacteria
employ
cellbas
anim
studi
list
supplementari
tabl
e
coli
variant
made
describ
ndmhk
pcv
screen
serial
passag
ndmhk
antibioticfre
medium
loss
gene
confirm
pcr
suscept
test
cb
rbc
kindli
provid
livzon
pharmaceut
group
bi
nit
bi
purchas
sigmaaldrich
chemic
structur
ligand
use
shown
supplementari
fig
bi
edta
edta
ethylenediaminetetraacet
bi
nta
nta
nitrilotriacet
prepar
mix
bismuth
subcarbon
bio
appropri
amount
ligand
follow
reflux
overnight
solut
filter
hot
cool
natur
crystal
collect
wash
water
ethanol
next
day
bi
nac
nac
nacetylcystein
bi
gsh
gsh
glutathion
bi
tbc
tbc
tetrabromocatechol
prepar
mix
bi
appropri
amount
ligand
methanol
impur
remov
filter
result
solut
evapor
slowli
obtain
solid
product
bi
tpp
tpp
tetraphenylporphyrin
synthes
use
modifi
brief
ml
reflex
pyridin
contain
g
mmol
tpp
ad
g
bi
mmol
g
mmol
ad
h
later
reflex
h
larg
amount
pyridin
remov
via
rotari
evapor
result
thick
green
mixtur
left
dri
overnight
vacuum
remov
residu
solvent
green
solid
obtain
wash
chloroform
rotari
evapor
ensur
pyridin
solvent
remov
darkgreen
solid
purifi
silica
gel
column
compound
purifi
wash
column
first
chloroform
chloroform
methanol
ratio
fabm
use
character
complex
mz
bi
calcul
bi
cpl
prepar
mix
mmol
dcaptopril
mmol
j
k
scientif
methanol
room
temperatur
constant
stir
overnight
color
chang
colorless
yellow
occur
methanol
remov
vacuum
result
yellow
solid
product
wash
success
ethanol
water
recrystal
methanol
yield
product
nmr
mhz
ppm
h
h
h
h
h
h
h
j
hz
mz
peak
mz
correspond
calcul
bi
pcm
prepar
mix
mmol
dpenicillamin
mmol
j
k
scientif
methanol
stir
result
immedi
color
chang
colorless
pale
yellow
mixtur
stir
overnight
room
temperatur
remain
solid
filter
solvent
filtrat
remov
vacuum
result
solid
recrystal
methanol
yield
yellow
solid
product
nmr
mhz
ppm
h
h
h
esim
mz
peak
mz
correspond
bil
calcul
calcul
calcul
calcul
respect
plasmid
use
templat
pcr
purifi
use
gel
extract
kit
qiaprep
spin
miniprep
kit
qiagen
pcr
primer
synthes
thermo
fisher
list
supplementari
tabl
pcr
perform
use
kod
hot
start
dna
polymeras
novagen
base
reaction
condit
describ
protocol
manufactur
restrict
enzym
use
directli
new
england
biolab
amplifi
gene
subsequ
insert
plasmid
incorpor
ntermin
histag
use
dna
ligas
form
vector
respect
express
vector
variant
gener
pcr
use
standard
protocol
phusion
sitedirect
mutagenesi
kit
new
england
lab
templat
construct
plasmid
subsequ
transform
compet
cell
molecular
clone
singl
coloni
e
coli
transform
respect
mbl
inocul
lb
medium
suppli
kanamycin
grown
protein
overexpress
induc
use
mm
iptg
supplement
mm
bacteri
cultur
incub
overnight
purifi
respect
protein
cultur
cell
harvest
centrifug
g
resuspend
lysi
buffer
mm
hepe
nacl
mm
pmsf
ph
cell
icecool
lyse
sonic
centrifug
g
min
remov
major
cell
debri
supernat
filter
use
minisart
syring
filter
remov
remain
larg
insolubl
cell
debri
appli
ml
ni
ii
load
hitrap
chelat
column
ge
healthcar
rate
ml
column
wash
use
five
column
volum
wash
buffer
mm
hepe
nacl
mm
imidazol
ph
protein
elut
use
four
column
volum
buffer
gradient
amount
imidazol
subsequ
dialyz
cleavag
buffer
mm
hepe
nacl
ph
ntermin
histag
fusion
protein
cleav
ad
nih
unit
thrombin
h
mild
shake
cleav
histag
separ
result
protein
pass
ni
ii
nta
column
use
wash
buffer
protein
flowthrough
fraction
enzym
purifi
use
hiload
superdex
pg
gel
filtrat
column
sampl
concentr
use
amicon
centrifug
filter
devic
millipor
separ
aliquot
dialysi
storag
buffer
mm
hepe
nacl
ph
longterm
storag
freshli
prepar
nm
mm
hepesna
ph
mm
nacl
first
incub
variou
concentr
cb
h
mix
equal
volum
mm
mer
assay
perform
cm
quartz
cuvett
use
kinet
mode
varian
uvvis
spectrophotomet
decreas
absorb
nm
due
ringopen
mer
monitor
everi
second
durat
min
reaction
complet
initi
rate
extract
calcul
reaction
curv
fit
curv
uvvi
spectra
collect
varian
cari
spectrophotomet
rate
nm
use
quartz
cuvett
ambient
temperatur
aliquot
mm
bi
nta
stock
solut
stepwis
titrat
sampl
titrat
buffer
mm
hepe
mm
nacl
ph
uvvi
spectra
record
rang
nm
least
min
addit
bind
bi
iii
monitor
increas
absorpt
nm
due
lmct
involv
cystein
residu
uv
titrat
curv
fit
nonlinear
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
frac
max
mathrm
p
left
left
k
mathrm
c
mathrm
c
mathrm
p
right
sqrt
left
c
mathrm
p
c
mathrm
k
mathrm
right
mathrm
c
mathrm
p
right
end
document
stand
uv
absorb
intens
imax
maxim
uv
absorb
cp
cm
refer
total
concentr
protein
ligand
respect
kd
dissoci
constant
dissoci
constant
deriv
kdka
kd
dissoci
constant
bi
nta
determin
nonlinear
ka
format
constant
bi
nta
log
ka
monitor
displac
zn
ii
bi
iii
icpm
employ
accur
quantifi
content
variou
purifi
sampl
purifi
dissolv
tracemetalfre
icpm
buffer
contain
mm
hepe
ph
incub
variou
concentr
cb
h
mild
shake
sampl
subsequ
dialyz
icpm
buffer
remov
unboundmet
ion
acidifi
subsequ
analyz
use
icpm
spectromet
agil
agil
technolog
ca
usa
intern
standard
content
use
quantifi
protein
concentr
investig
whether
bismuth
inhibit
enzym
revers
enzym
activ
compar
upon
supplement
zn
ii
bibound
nm
prepar
preincub
apobound
cb
h
follow
remov
unbound
bi
iii
bound
bi
verifi
icpm
protein
solut
mix
concentr
molar
equival
mer
chang
absorb
nm
monitor
varian
cari
uvvis
spectrophotomet
calcul
reaction
rate
reaction
rate
addit
molar
equival
normal
metal
content
bibound
treat
zn
ii
measur
analyz
icpm
describ
previou
section
limit
perform
examin
vitro
stabil
differ
form
brief
aliquot
pure
apobound
znbound
bibound
treat
proteinas
k
fungal
invitrogen
umg
mm
tri
mm
ph
aliquot
taken
variou
time
interv
reaction
quench
mm
pmsf
sampl
subject
sdspage
coomassi
blue
stain
pagerul
prestain
protein
ladder
thermo
use
standard
marker
nm
incub
bi
nit
h
gentl
shake
assay
perform
micropl
reader
k
final
assay
buffer
contain
mm
hepe
ph
mm
nacl
mer
substrat
rang
control
experi
also
perform
absenc
inhibitor
condit
km
vmax
uninhibit
inhibit
reaction
obtain
fit
data
doubl
reciproc
plot
protein
level
determin
sdspage
follow
western
blot
wholecel
lysat
differ
e
coli
stain
typic
logarithm
phase
cultur
lyse
sonic
sonic
buffer
mm
hepe
ph
mm
nacl
bacteri
lysat
harvest
centrifug
normal
accord
total
protein
concentr
quantifi
bicinchonin
acid
assay
pierc
bca
protein
assay
kit
thermo
scientif
sampl
resolv
sdspage
gel
electrotransf
pvdf
membran
hybondp
ge
healthcar
pagerul
prestain
protein
ladder
thermo
use
standard
marker
dilut
monoclon
antibodi
novu
biolog
secondari
antibodi
goat
antimous
immunoglobulin
g
igg
alkalin
phosphatas
ap
conjug
appli
perform
standard
blot
procedur
band
calorimetr
develop
specifi
ratio
substrat
compris
nitroblu
phosphat
nbtbcip
min
softwar
use
quantifi
signal
band
analysi
softwar
graphpad
prism
version
mac
graphpad
softwar
la
jolla
ca
usa
wwwgraphpadcom
use
analyz
result
plot
cellular
thermal
shift
assay
perform
accord
standard
clinic
isol
e
coli
ndmhk
cultur
overnight
absenc
presenc
bi
iii
compound
ie
cb
bi
nac
bi
nit
bacteri
pellet
harvest
wash
pb
time
cell
suspens
aliquot
pcr
tube
heat
treatment
perform
design
temperatur
rang
min
thermal
cycler
tube
cool
immedi
room
temperatur
anoth
min
heat
heat
procedur
repeat
three
cycl
cell
lysi
sampl
two
cycl
liquid
nitrogen
thermal
cycler
set
sampl
vortex
gentli
cycl
centrifug
g
obtain
supernat
second
cycl
finish
sampl
subject
western
blot
analysi
detect
quantif
content
describ
metal
salt
use
screen
involv
bismuth
nitrat
bi
iii
gallium
nitrat
ga
iii
sodium
stiboglucon
sb
v
chromium
chlorid
cr
iii
cobalt
chlorid
co
ii
nickel
chlorid
ni
ii
ruthenium
chlorid
ru
ii
copper
sulfat
cu
ii
briefli
differ
concentr
metal
compound
ad
lb
medium
contain
mer
plate
cfu
logarithm
cultur
ndmhk
ad
well
plate
coincub
overnight
growth
inhibit
bacteria
monitor
od
read
nm
serial
dilut
lb
agar
plate
well
antibiot
metal
compound
serv
growth
control
well
bacteria
ad
serv
background
control
test
perform
triplic
inhibit
calcul
cfu
count
serial
dilut
pb
spot
lb
agar
plate
mic
valu
determin
standard
broth
microdilut
method
clinic
laboratori
standard
institut
clsi
briefli
bacteri
cell
cultur
lb
broth
overnight
rpm
od
measur
nm
bacteri
densiti
adjust
cfu
check
cfu
count
agar
plate
afterward
test
antibiot
bi
iii
compound
ad
triplic
individu
well
flatbottom
plate
perform
serial
dilut
follow
addit
prepar
bacteri
inocula
plate
incub
overnight
well
antibiot
bi
iii
compound
serv
growth
control
well
bacteria
ad
serv
background
control
mic
determin
lowest
concentr
drug
could
inhibit
growth
microorgan
visual
read
od
read
nm
use
microtit
plate
reader
test
ndmrosetta
ox
growth
condit
briefli
goe
follow
overnight
cultur
ndmrosetta
dilut
fresh
lb
medium
regrew
od
overexpress
induc
addit
mm
isopropyl
iptg
h
follow
suscept
test
perform
describ
microdilut
mic
mbc
assay
section
methodolog
use
result
bacteri
pellet
supplement
iptg
test
growth
condit
briefli
goe
follow
overnight
cultur
dilut
fresh
lb
medium
regrew
od
overexpress
induc
addit
isopropyl
iptg
h
follow
suscept
test
perform
describ
microdilut
mic
mbc
assay
section
methodolog
use
result
bacteri
pellet
supplement
iptg
end
mic
assay
aliquot
well
contain
specifi
antimicrobi
concentr
isol
test
appli
lb
agar
plate
incub
overnight
result
growth
lack
growth
examin
overnight
cultur
lowest
concentr
inhibit
origin
cultur
taken
mbc
drug
combin
test
antibiot
bi
iii
compound
coad
concentr
eight
time
higher
mic
drug
test
alon
procedur
kept
strictli
fici
determin
accord
follow
equat
fici
fica
ficb
camica
cbmicb
mica
micb
mic
valu
compound
b
respect
function
alon
ca
cb
concentr
compound
b
effect
combin
synerg
defin
fici
indiffer
defin
fici
antagon
defin
volum
set
mic
bi
iii
except
bi
nac
determin
fic
valu
determin
perform
least
triplic
differ
day
time
kill
assay
use
explor
synergi
mer
bi
iii
compound
typic
assay
ndmhk
cultur
overnight
dilut
lb
broth
h
reach
log
phase
initi
bacteri
densiti
adjust
cfu
expos
mer
bi
iii
compound
either
alon
combin
lb
broth
drug
serv
control
aliquot
bacteri
suspens
withdrawn
differ
time
interv
h
inspect
bacteri
viabil
agar
plate
concentr
drug
use
test
mer
cb
bi
nac
data
three
independ
experi
averag
plot
cfu
vs
time
h
time
point
h
assay
triplic
perform
three
time
differ
day
five
coloni
ndmhk
grown
lb
broth
bi
iii
compound
variou
concentr
ad
respect
well
plate
triplic
bacteri
cell
pellet
collect
h
incub
follow
wash
pb
six
time
harvest
bacteri
pellet
dissolv
overnight
use
thermolyn
dribath
dissolv
sampl
dilut
appropri
concentr
quantif
metal
icpm
agil
agil
technolog
ca
usa
intern
standard
metal
quantif
triplic
averag
valu
use
crystal
nativ
grown
use
hang
drop
vapor
diffus
method
crystal
grown
use
precipit
contain
bistri
ph
peg
wv
mm
lprolin
one
microlit
protein
solut
concentr
mg
mix
precipit
seal
incub
diamondlik
rectangular
crystal
appear
within
day
seed
grew
full
size
within
week
gener
diffract
resolut
crystal
crosslink
vv
glutaraldehyd
min
soak
chelat
solut
sodium
acet
ph
peg
glycerol
mm
edta
overnight
crystal
wash
three
time
cryoprotect
solut
bistri
ph
peg
glycerol
soak
bismuth
compound
soak
done
h
ad
mm
tcep
mm
bismuth
compound
bismuth
nitrat
cb
crystal
wash
cryoprotect
solut
four
time
flashfrozen
liquid
nitrogen
two
data
set
collect
shanghai
synchrotron
radiat
facil
ssrf
two
specif
wavelength
cross
absorpt
edg
element
bi
excit
scan
perform
confirm
absenc
zinc
ion
soak
diffract
data
process
ssrf
molecular
replac
perform
use
program
suit
ampicillinbound
pdb
code
search
model
cycl
refin
anomal
data
done
use
care
manual
rebuild
anomal
signal
strength
compar
two
data
set
collect
wavelength
bi
iii
occup
refin
base
bi
anomal
signal
earli
refin
stage
assess
atom
bfactor
later
stage
tl
refin
incorpor
later
refin
process
solvent
ad
automat
coot
manual
inspect
modifi
final
model
analyz
data
collect
model
refin
statist
summar
supplementari
tabl
measur
ndmhk
cfu
plate
onto
lb
agar
contain
mer
cb
differ
concentr
incub
h
incub
plate
observ
coloni
four
coloni
pick
recultur
follow
measur
mic
valu
mic
mer
greater
origin
valu
determin
higherlevel
resist
mutant
coloni
concentr
restrict
growth
mutant
coloni
determin
mpc
ident
experi
higherlevel
resist
mutant
coloni
enumer
rel
mutat
frequenc
mic
strainantibiot
pair
calcul
proport
resist
coloni
per
inoculum
serial
passag
overnight
cultur
ndmhk
dilut
cfu
lb
broth
asdilut
bacteri
suspens
ad
well
plate
supplement
drug
mic
respect
drug
concentr
vitro
select
increas
mic
respect
bacteri
passag
plate
incub
growth
cultur
check
h
interv
cultur
second
highest
concentr
allow
growth
perform
dilut
fresh
medium
supplement
concentr
drug
mer
mic
set
combin
mer
cb
mic
set
mer
cb
vitro
passag
repeat
day
mic
mer
determin
everi
four
passag
mdck
cell
cultur
minimum
essenti
media
mem
supplement
fetal
bovin
serum
fb
grown
atmospher
day
mdck
cell
seed
per
well
plate
incub
describ
h
ensur
confluenc
logarithm
cultur
ndmhk
wash
pb
three
time
resuspend
fb
result
initi
bacteri
densiti
cfu
bacteri
suspens
ad
well
substitut
previou
mdck
cultur
medium
plate
centrifug
g
min
incub
anoth
h
execut
bacteri
infect
multipl
infect
moi
use
two
infect
model
examin
viz
cellassoci
bacteri
infect
cellinvad
bacteri
infect
cellassoci
bacteria
herein
defin
bacteria
attach
penetr
transcytos
mdck
cell
cellinvad
bacteria
defin
bacteria
penetr
transcytos
mdck
cell
cellinvad
infect
infect
cell
incub
cultur
medium
supplement
ciprofloxacin
h
remov
extracellular
bacteria
treat
cell
wash
vigor
pb
six
time
replenish
cultur
medium
cellassoci
infect
infect
cell
wash
vigor
pb
six
time
remov
unbound
bacteria
infect
mdck
cell
expos
either
mer
cb
combin
overnight
ident
cell
cultur
condit
cell
absenc
drug
serv
control
bacteri
load
examin
lyse
mdck
cell
triton
pb
serial
dilut
result
lysat
enumer
bacteri
coloni
agar
plate
assay
perform
triplic
repeat
three
time
result
express
averag
sd
experi
approv
perform
accord
guidelin
approv
committe
use
live
anim
teach
research
culatr
univers
hong
kong
total
femal
balbc
mice
g
purchas
charl
river
laboratori
inc
use
mous
studi
anim
random
cage
experi
mucinassist
model
infect
bacteria
overnight
cultur
ndmhk
perform
dilut
ml
lb
broth
regrew
flask
h
shake
rpm
bacteri
pellet
collect
wash
pb
buffer
three
time
use
mice
infect
intraperiton
ip
dose
cfu
bacteria
pb
supplement
mucin
four
group
mice
ip
administ
h
post
infect
aliquot
vehicl
control
monotherapi
mer
mg
cb
mg
combin
therapi
n
respect
twicedaili
treatment
via
ip
inject
continu
throughout
whole
experiment
cours
infect
bacteria
oper
infect
similar
use
ndmhk
except
ndmhk
pcv
use
infectioncaus
bacteria
two
group
mice
ip
administ
h
postinfect
aliquot
vehicl
control
monotherapi
mer
mg
n
group
twicedaili
treatment
via
ip
inject
continu
throughout
whole
experiment
cours
bodi
weight
mice
surviv
monitor
till
endpoint
experi
mucinfre
surviv
experi
mice
infect
dose
cfu
ndmhk
pb
mice
receiv
monotherapi
mer
mg
cb
mg
combin
therapi
h
post
infect
n
group
experiment
oper
condit
kept
mucinassist
model
bodi
weight
mice
surviv
monitor
endpoint
till
endpoint
experi
coordin
structur
factor
zincbound
nativ
bi
iii
bound
deposit
protein
data
bank
access
code
respect
data
avail
correspond
author
upon
reason
request
